1 citations
,
January 2018 in “Medical Science and Discovery” The document's conclusion cannot be provided as the content is not available for parsing.
March 2024 in “Journal of cosmetic dermatology” Isotretinoin can effectively reduce symptoms of frontal fibrosing alopecia.
April 2025 in “International Journal of Dermatology” Renaming frontal fibrosing alopecia to a syndrome could improve diagnosis and treatment.
January 2024 in “Updates in clinical dermatology” Frontal fibrosing alopecia is a scarring hair loss condition mainly affecting postmenopausal women, with unclear causes.
4 citations
,
November 2024 in “International Journal of Biological Macromolecules” Zinc sulfide cellulose scaffolds can reduce scarring and promote hair growth.
October 2021 in “Scholarworks (University of Massachusetts Amherst)” FERONIA is crucial for plant growth, pollen tube reception, and sugar signaling.
February 2026 in “American Journal of Clinical Dermatology” Radiotherapy can cause skin fibrosis, which is often overlooked and needs better treatment and evaluation.
January 2024 in “Pharmacoepidemiology” Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.
3 citations
,
August 2020 in “Case Reports in Dermatology” Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.
April 2023 in “Journal of Investigative Dermatology” ENERGI-F701 solution was found to be more effective and safer than Regaine® 2% minoxidil solution in treating female pattern hair loss, with increased hair density and less side effects.
3 citations
,
January 2008 in “Drug Safety” Finasteride can help regrow hair in male pattern baldness.
January 2024 in “Reproductive toxicology” Hesperidin helps protect against testicular damage caused by finasteride.
Finasteride may reduce heart damage in rats.
July 2015 in “Pharmacological Reports” Finasteride weakens the bone-protective effects of certain blockers in low androgen conditions.
137 citations
,
March 2006 in “Cns Drug Reviews” Finasteride treats enlarged prostate and hair loss, but may cause side effects in some patients.
June 2008 in “Experimental Dermatology” 17-beta estradiol and prednisolone may help regrow hair damaged by chemotherapy.
April 2017 in “Leukemia research” Tofacitinib helped most teenagers in the study regrow hair with mild side effects.
3 citations
,
July 2024 in “Archives of Dermatological Research” Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.
October 2021 in “International Journal of Andrology” Finasteride, a hair loss drug, has unaddressed sexual side effects due to the manufacturer's inadequate safety measures and lack of additional studies.
2 citations
,
January 2016 in “Andrology”
4 citations
,
May 2018 in “BMC Musculoskeletal Disorders” Dutasteride and finasteride have similar risk for osteoporosis and fractures in older men.
2 citations
,
August 2025 in “JAAD reviews.” Frontal fibrosing alopecia significantly affects men, often causing hair loss in eyebrows, beard, and sideburns.
February 2023 in “Journal of Microencapsulation” The finasteride nanosystem with trehalose is stable and effective for topical hair loss treatment.
March 2025 in “Clinical and Experimental Dermatology” Older patients without prior JAK inhibitor treatment respond best to tofacitinib for alopecia areata.
January 2026 in “Figshare” Finasteride can cause melasma, especially in people with darker skin.
1 citations
,
June 2025 in “European Journal of Clinical Pharmacology” Finasteride may increase the risk of suicidality and depression, especially in younger people.
18 citations
,
March 2006 in “Expert Review of Neurotherapeutics” The document concludes that managing side effects of MS therapies is crucial for treatment success and patient adherence.
December 2023 in “Alzheimer's & Dementia” Long-term use of a drug for hair loss and prostate issues can cause metabolic problems and depression-like behavior in young male rats.
September 2010 in “Institutional Repositories DataBase (IRDB)” Sorafenib can cause a temporary skin condition that goes away after stopping the drug.